Evidence map›Paper›PMID 32606250›Full record

ArticleExperimental neurobiology2020

ERK Regulates NeuroD1-mediated Neurite Outgrowth via Proteasomal Degradation.

Tae-Young Lee, In-Su Cho, Narayan Bashyal, Francisco J Naya, Ming-Jer Tsai, Jeong Seon Yoon, Jung-Mi Choi, Chang-Hwan Park, Sung-Soo Kim, Haeyoung Suh-Kim

Open access · diamondAbstract read
In one paragraph

Article in Experimental neurobiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Congenital hyperinsulinism due to NEUROD1 gene mutation.Annals of pediatric endocrinology & metabolism · 2025
    Article
  4. Potential of Alkaloids fromCurrent issues in molecular biology · 2025
    Article
  5. Nutrients · 2024
    Article
  6. Review
  7. Review
  8. Neural Stem Cell-based Regenerative Therapy: A New Approach to Diabetes Treatment.Endocrine, metabolic & immune disorders drug targets · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Tae-Young LeeDepartment of Anatomy, Ajou University School of Medicine, Suwon 16499, Korea.
In-Su ChoDepartment of Anatomy, Ajou University School of Medicine, Suwon 16499, Korea.
Narayan BashyalDepartment of Anatomy, Ajou University School of Medicine, Suwon 16499, Korea.
Francisco J NayaDepartment of Biology, Life Science and Engineering Building, Boston University, Boston, MA 00215, USA.
Ming-Jer TsaiDepartment of Medicine and Program in Developmental Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Jeong Seon YoonDepartment of Anatomy, Ajou University School of Medicine, Suwon 16499, Korea.
Jung-Mi ChoiDepartment of Anatomy, Ajou University School of Medicine, Suwon 16499, Korea.
Chang-Hwan ParkGraduate School of Biomedical Science and Engineering, Hanyang University, Seoul 04763, Korea.
Sung-Soo KimDepartment of Anatomy, Ajou University School of Medicine, Suwon 16499, Korea.
Haeyoung Suh-KimDepartment of Anatomy, Ajou University School of Medicine, Suwon 16499, Korea.
Ajou University · KRBaylor College of Medicine · USBoston University · USHanyang University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurogenic differentiation 1 (NeuroD1) is a class B basic helix-loop-helix (bHLH) transcription factor and regulates differentiation and survival of neuronal and endocrine cells by means of several protein kinases, including extracellular signal-regulated kinase (ERK). However, the effect of phosphorylation on the functions of NeuroD1 by ERK has sparked controversy based on context-dependent differences across diverse species and cell types. Here, we evidenced that ERK-dependent phosphorylation controlled the stability of NeuroD1 and consequently, regulated proneural activity in neuronal cells. A null mutation at the ERK-dependent phosphorylation site, S274A, increased the half-life of NeuroD1 by blocking its ubiquitin-dependent proteasomal degradation. The S274A mutation did not interfere with either the nuclear translocation of NeuroD1 or its heterodimerization with E47, its ubiquitous partner and class A bHLH transcription factor. However, the S274A mutant increased transactivation of the E-box-mediated gene and neurite outgrowth in F11 neuroblastoma cells, compared to the wild-type NeuroD1. Transcriptome and Gene Ontology enrichment analyses indicated that genes involved in axonogenesis and dendrite development were downregulated in NeuroD1 knockout (KO) mice. Overexpression of the S274A mutant salvaged neurite outgrowth in NeuroD1-deficient mice, whereas neurite outgrowth was minimal with S274D, a phosphomimicking mutant. Our data indicated that a longer protein half-life enhanced the overall activity of NeuroD1 in stimulating downstream genes and neuronal differentiation. We propose that blocking ubiquitin-dependent proteasomal degradation may serve as a strategy to promote neuronal activity by stimulating the expression of neuron-specific genes in differentiating neurons.

Indexed as

Extracellular signal-regulated kinaseNeurite outgrowthNeurogenic differentiation factor 1Phosphorylation

Identifiers

PMID32606250
PMCPMC7344372
OpenAlexW3040411165

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.